REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study

REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study

Introduction: In the REFLECT trial, lenvatinib was found to be non-inferior compared to sorafenib in terms of Overall Survival. Here, we analyze the effects of lenvatinib in the real-life experience of several centers across the world, and to identify clinical factors that could be significantly ass...

Full description

Bibliographic Details
Main Authors: Andrea Casadei-Gardini, Margherita Rimini, Masatoshi Kudo, Shigeo Shimose, Toshifumi Tada, Goki Suda, Myung Ji Goh, Andre Jefremow, Mario Scartozzi, Giuseppe Cabibbo, Claudia Campani, Emiliano Tamburini, Francesco Tovoli, Kazuomi Ueshima, Tomoko Aoki, Hideki Iwamoto, Takuji Torimura, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Ei Itobayashi, Hidenori Toyoda, Naoya Sakamoto, Takuya Sho, Wonseok Kang, Jürgen Siebler, Markus Friedrich Neurath, Valentina Burgio, Stefano Cascinu
Format: Article
Language:English
Published: Karger Publishers 2022-07-01
Series:Liver Cancer
Online Access:https://beta.karger.com/Article/FullText/525145

Internet

https://beta.karger.com/Article/FullText/525145

Similar Items